Risonet150 mg

Established / FDA-Approved Uses

• Treatment and prevention of postmenopausal osteoporosis - Risonet reduces the risk of vertebral and hip fractures in postmenopausal women.
• Treatment to increase bone mass in men with osteoporosis.
• Prevention and treatment of glucocorticoid-induced osteoporosis in men and women initiating or continuing long-term (expected duration ≥3 months) systemic glucocorticoid therapy at a dose equivalent to ≥7.5 mg prednisone daily.
• Treatment of Paget's disease of bone in men and women with moderate to severe disease.

Notes on Use

Risonet is used as part of a comprehensive treatment plan that may include adequate calcium and vitamin D intake, weight-bearing exercise, and lifestyle modification (smoking cessation, limiting alcohol) as advised by the physician.

Risedronate Sodium is available as oral tablets in strengths typically including 5 mg, 30 mg, 35 mg, 75 mg, and 150 mg, depending on the dosing regimen and indication. Each tablet contains Risedronate Sodium as the active ingredient along with pharmaceutically inert excipients.

Risonet is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption, helping to preserve and, over time, increase bone mineral density. It is prescribed for the prevention and treatment of osteoporosis and for Paget's disease of bone. By slowing the rate of bone breakdown relative to bone formation, Risonet helps reduce the risk of fractures in patients with reduced bone mass.

Risonet belongs to the bisphosphonate class of medications, specifically a pyridinyl (nitrogen-containing) bisphosphonate. It is classified as a bone resorption inhibitor / anti-resorptive agent.

Pharmacodynamics

Risedronate Sodium binds to hydroxyapatite in bone and selectively inhibits osteoclast activity, reducing bone turnover and bone resorption without impairing bone mineralization. This shifts the balance of bone remodeling toward formation, leading to a net gain in bone mass over time.

Pharmacokinetics

Oral bioavailability of Risedronate Sodium is low (approximately 0.6%) and is further reduced when taken with food or calcium/mineral-containing products. Once absorbed, a portion binds to bone; the remainder is excreted unchanged, primarily by the kidneys. The terminal elimination half-life associated with bone binding is prolonged, reported at approximately 480 hours.

Risonet must be taken on an empty stomach with plain water only, at least 30 minutes before any food, drink, or other medication, and the patient must remain upright (sitting or standing) for at least 30 minutes afterward without lying down, to prevent esophageal irritation. See Dosage and Administration for complete instructions.

Clinically Significant Interactions

• Calcium, magnesium, aluminum, and iron-containing products (including antacids and supplements): Significantly reduce absorption of Risonet when taken together. These products must be taken at least 30 minutes after Risonet, or at a different time of day entirely.
• Other oral medications: Because co-administration reduces absorption, other oral drugs should also be separated from Risonet dosing by at least 30 minutes.
• NSAIDs and aspirin: Concomitant use may increase the risk of upper gastrointestinal irritation, since both bisphosphonates and NSAIDs can independently irritate the GI mucosa; caution is advised, particularly in patients with additional GI risk factors.

Common

• Dyspepsia, abdominal pain, nausea
• Musculoskeletal (bone, joint, or muscle) pain
• Back pain
• Headache

Less Common / Serious

• Esophagitis, esophageal ulcer or erosion (related to not following administration instructions)
• Osteonecrosis of the jaw (rare)
• Atypical femur fractures (rare, with long-term use)
• Hypocalcemia
• Iritis/uveitis (rare eye inflammation)

Patients should seek medical attention for severe or persistent gastrointestinal symptoms, new hip/groin/thigh pain, or jaw pain/swelling while taking Risonet.

Risonet is generally not indicated in pregnancy, as osteoporosis predominantly affects postmenopausal women. Animal studies have shown adverse effects on fetal development, and because bisphosphonates are incorporated into bone matrix and released slowly over time, the effect of this on a developing fetus in a future pregnancy is not fully known. Risonet should be used in pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus, and only under close physician supervision.

It is not known whether Risonet passes into breast milk. Because of the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of treatment to the mother, in consultation with a physician.

Esophageal and Upper GI Irritation

Strict adherence to administration instructions is essential (see Dosage and Administration) to minimize the risk of esophageal irritation, esophagitis, or ulceration. Risonet should be discontinued and a physician contacted if symptoms of esophageal irritation develop (dysphagia, new or worsening heartburn, chest pain, or pain on swallowing).

Osteonecrosis of the Jaw (ONJ)

Rare cases of osteonecrosis of the jaw have been reported with bisphosphonate use, more frequently with intravenous bisphosphonates in cancer patients but also reported with oral bisphosphonates such as Risonet. Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroid use, and poor oral hygiene. A dental examination is advisable before starting therapy in at-risk patients.

Atypical Femur Fractures

Atypical, low-trauma subtrochanteric and femoral shaft fractures have been reported with long-term bisphosphonate use, including Risonet. Patients should be advised to report new or unusual thigh, hip, or groin pain. Periodic re-evaluation of the need for continued therapy is recommended (see Duration of Treatment).

Hypocalcemia and Mineral Metabolism

Hypocalcemia must be corrected before starting Risonet (see Contraindications). Adequate calcium and vitamin D intake should be ensured during treatment.

Renal Impairment

Use with caution in mild-to-moderate renal impairment; not recommended in patients with severe renal impairment (see Contraindications).

Overdose with Risonet may result in hypocalcemia, hypophosphatemia, and upper gastrointestinal adverse effects such as upset stomach, heartburn, esophagitis, gastritis, or ulcer. Milk or antacids containing calcium or magnesium may be given to bind the drug if taken recently, but vomiting should not be induced and the patient should remain in an upright position. In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services without delay.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

No dosage adjustment is required in patients with mild-to-moderate renal impairment. Risonet is not recommended in patients with severe renal impairment (see Contraindications).

Hepatic Impairment

No specific studies have been conducted in patients with hepatic impairment; no dosage adjustment is considered necessary, as Risonet is not significantly metabolized by the liver.

Elderly

No dosage adjustment is required based on age alone; efficacy and safety have been demonstrated in elderly populations, who are also the primary population treated for osteoporosis.

Pediatric

Safety and efficacy in pediatric patients have not been established (see Pediatric Uses).

The optimal duration of bisphosphonate therapy, including Risonet, has not been definitively established for all patients. Treatment duration is typically individualized, often 3-5 years or longer, based on fracture risk, bone mineral density response, and periodic physician reassessment. For Paget's disease, a standard course is 2 months, with retreatment considered only after relapse is confirmed and following an interval off therapy. Patients should not stop or continue Risonet beyond the prescribed duration without consulting their physician.

Bisphosphonate (pyridinyl bisphosphonate); bone resorption inhibitor / anti-resorptive agent.

Risedronate Sodium binds avidly to bone mineral (hydroxyapatite) and is preferentially taken up by osteoclasts during bone resorption. It inhibits farnesyl pyrophosphate synthase, a key enzyme in the osteoclast cholesterol/mevalonate pathway, disrupting osteoclast cytoskeletal organization and function, and promoting osteoclast apoptosis. This reduces bone resorption, allowing bone formation to proceed relatively unopposed and leading to a net increase in bone mineral density over time.

C

Risonet is not indicated for use in pediatric patients. Safety and efficacy in patients under 18 years of age have not been established.